Update Mammakarzinom 2021 Teil 2 – fortgeschrittene Stadien, Langzeitfolgen und Biomarker

Zusammenfassung

In dieser Übersichtsarbeit werden relevante Aspekte kürzlich veröffentlichter Studien zur Behandlung von Brustkrebspatientinnen in fortgeschrittenen Stadien sowie zu Biomarkern beim Mammakarzinom zusammenfassend dargestellt und diskutiert. In den letzten Jahren wurde eine Vielzahl von Medikamenten für alle molekularen Subtypen bis zu Phase-III-Studien entwickelt. In Bezug auf die Immuncheckpoint-Inhibitoren wurde in letzter Zeit für die metastasierte Situation der optimale Chemotherapie-Kombinationspartner diskutiert. Mit oralen Taxanen könnte sich eine neue Art von oralen Chemotherapien etablieren. Die Datenlage zu Biomarkern für die Anwendung der CDK4/6-Inhibitoren wächst, was auch eine Weiterentwicklung für andere molekulare Subtypen bedeuten könnte. Beim HER2+, metastasierten Mammakarzinom wurden neue Substanzen entwickelt, die auch nach massiver Vorbehandlung und/oder zerebraler Metastasierung noch gute Remissionen zeigen. Ebenso wächst das Wissen um zielgerichtete Therapien mit Antikörper-Wirkstoff-Konjugaten (ADC) gegen Trop-2, die bei triple-negativen Mammakarzinomen (TNBC) eine therapeutische Bereicherung bedeuten könnten. Des Weiteren steht das Verständnis des Fertilitätserhaltes nach einer Brustkrebserkrankung im klinischen Fokus. Hier schaffen gepoolte Analysen einen neuen Einblick.

Schlüsselwörter

fortgeschrittenes Mammakarzinom - Biomarker - Therapie - Prognose

Publication History

Received: 17 March 2021

Accepted after revision: 23 March 2021

Article published online:
03 May 2021

• References/Literatur

• 1 Ditsch N, Untch M, Thill M. et al. AGO Recommendations for the Diagnosis and Treatment of Patients with Early Breast Cancer: Update 2019. Breast Care (Basel) 2019; 14: 224-245
• 2 Ditsch N, Untch M, Kolberg-Liedtke C. et al. AGO Recommendations for the Diagnosis and Treatment of Patients with Locally Advanced and Metastatic Breast Cancer: Update 2020. Breast Care (Basel) 2020; 15: 294-309
• 3 Tesch H, Müller V, Wöckel A. et al. Update Breast Cancer 2020 Part 4 – Advanced Breast Cancer. Geburtshilfe Frauenheilkd 2020; 80: 1115-1122
• 4 Schneeweiss A, Hartkopf AD, Müller V. et al. Update Breast Cancer 2020 Part 1 – Early Breast Cancer: Consolidation of Knowledge About Known Therapies. Geburtshilfe Frauenheilkd 2020; 80: 277-287
• 5 Lüftner D, Schneeweiss A, Hartkopf AD. et al. Update Breast Cancer 2020 Part 2 – Advanced Breast Cancer: New Treatments and Implementation of Therapies with Companion Diagnostics. Geburtshilfe Frauenheilkd 2020; 80: 391-398
• 6 Huober J, Schneeweiss A, Hartkopf AD. et al. Update Breast Cancer 2020 Part 3 – Early Breast Cancer. Geburtshilfe Frauenheilkd 2020; 80: 1105-1114
• 7 Miles DW, Gligorov J, André F. et al. Primary results from IMpassion131, a double-blind placebo-controlled randomised phase III trial of first-line paclitaxel (PAC) ± atezolizumab (atezo) for unresectable locally advanced/metastatic triple-negative breast cancer (mTNBC). Ann Oncol 2020; 31 (Suppl. 04) S1142-S1215 doi:10.1016/annonc/annonc325
• 8 Schmid P, Adams S, Rugo HS. et al. IMpassion130: updated overall survival (OS) from a global, randomized, double-blind, placebo-controlled, Phase III study of atezolizumab (atezo) + nab-paclitaxel (nP) in previously untreated locally advanced or metastatic triple-negative breast cancer (mTNBC). J Clin Oncol 2019; 37 (15 Suppl.): 1003-1003
• 9 Schmid P, Adams S, Rugo HS. et al. Atezolizumab and Nab-Paclitaxel in Advanced Triple-Negative Breast Cancer. N Engl J Med 2018; 379: 2108-2121
• 10 Cortes J, Cescon DW, Rugo HS. et al. KEYNOTE-355: Randomized, double-blind, phase III study of pembrolizumab + chemotherapy versus placebo + chemotherapy for previously untreated locally recurrent inoperable or metastatic triple-negative breast cancer. J Clin Oncol 2020; 38 (15 Suppl.): 1000
• 11 Rugo HS, Schmid P, Cescon DW. et al. Additional efficacy endpoints from the phase 3 KEYNOTE-355 study of pembrolizumab plus chemotherapy vs. placebo plus chemotherapy as first-line therapy for locally recurrent inoperable or metastatic triple-negative breast cancer. San Antonio Breast Cancer Symposium 2020; 2020: GS3-01 Accessed March 16 2021 at: https://www.abstractsonline.com/pp8/%23!/9223/presentation/1725
• 12 Umanzor G, Cutler DL, Barrios FJ. et al. Oral paclitaxel with encequidar: The first orally administered paclitaxel shown to be superior to IV paclitaxel on confirmed response and survival with less neuropathy: A phase III clinical study in metastatic breast cancer. Cancer Res 2020; 80 (Suppl. 04) GS6-01
• 13 Jang SH, Wientjes MG, Au JL. Kinetics of P-glycoprotein-mediated efflux of paclitaxel. J Pharmacol Exp Ther 2001; 298: 1236-1242
• 14 Umanzor G, Rugo HS, Barrios FJ. et al. Oral Paclitaxel and Encequidar (oPac+E) versus IV paclitaxel (IVPac) in the Treatment of Metastatic Breast Cancer (mBC) Patients (Study KX-ORAX-001): Progression Free Survival (PFS) and Overall Survival (OS) Updates. San Antonio Breast Cancer Symposium 2020; 2020 (04) PD1-08 https://www.abstractsonline.com/pp8/%23!/9223/presentation/716
• 15 OʼShaughnessy J, Schwartzberg L, Piccart M. et al. Results from CONTESSA: A phase 3 study of tesetaxel plus a reduced dose of capecitabine versus capecitabine alone in patients with HER2-, hormone receptor + (HR+) metastatic breast cancer (MBC) who have previously received a taxane. San Antonio Breast Cancer Symposium 2020; 2020: GS4-01 Accessed March 16 2021. at: https://www.abstractsonline.com/pp8/%23!/9223/session/155
• 16 businesswire. Odonate Therapeutics Announces Discontinuation of Development of Tesetaxel. Accessed March 23, 2021 at: https://www.businesswire.com/news/home/20210322005211/en/Odonate-Therapeutics-Announces-Discontinuation-of-Development-of-Tesetaxel
• 17 Yardley DA, Ismail-Khan RR, Melichar B. et al. Randomized phase II, double-blind, placebo-controlled study of exemestane with or without entinostat in postmenopausal women with locally recurrent or metastatic estrogen receptor-positive breast cancer progressing on treatment with a nonsteroidal aromatase inhibitor. J Clin Oncol 2013; 31: 2128-2135
• 18 Dent R, Kim S-B, Oliveira M. et al. Double-blind placebo (PBO)-controlled randomized phase III trial evaluating first-line ipatasertib (IPAT) combined with paclitaxel (PAC) for PIK3CA/AKT1/PTEN-altered locally advanced unresectable or metastatic triple-negative breast cancer (aTNBC): primary results from IPATunity130 Cohort A. San Antonio Breast Cancer Symposium 2020; 2020: GS3-04 Accessed March 16 2021 at: https://www.abstractsonline.com/pp8/%23!/9223/presentation/672
• 19 Kim SB, Dent R, Im SA. et al. Ipatasertib plus paclitaxel versus placebo plus paclitaxel as first-line therapy for metastatic triple-negative breast cancer (LOTUS): a multicentre, randomised, double-blind, placebo-controlled, phase 2 trial. Lancet Oncol 2017; 18: 1360-1372
• 20 Sotiriou C, Pusztai L. Gene-expression signatures in breast cancer. N Engl J Med 2009; 360: 790-800
• 21 Finn RS, Dering J, Conklin D. et al. PD 0332991, a selective cyclin D kinase 4/6 inhibitor, preferentially inhibits proliferation of luminal estrogen receptor-positive human breast cancer cell lines in vitro. Breast Cancer Res 2009; 11: R77
• 22 Hortobagyi GN. Ribociclib for HR-Positive, Advanced Breast Cancer. N Engl J Med 2017; 376: 289
• 23 Slamon DJ, Neven P, Chia S. et al. Phase III Randomized Study of Ribociclib and Fulvestrant in Hormone Receptor-Positive, Human Epidermal Growth Factor Receptor 2-Negative Advanced Breast Cancer: MONALEESA-3. J Clin Oncol 2018; 36: 2465-2472
• 24 Slamon DJ, Neven P, Chia S. et al. Overall Survival with Ribociclib plus Fulvestrant in Advanced Breast Cancer. N Engl J Med 2020; 382: 514-524
• 25 Tripathy D, Im SA, Colleoni M. et al. Ribociclib plus endocrine therapy for premenopausal women with hormone-receptor-positive, advanced breast cancer (MONALEESA-7): a randomised phase 3 trial. Lancet Oncol 2018; 19: 904-915
• 26 Im SA, Lu YS, Bardia A. et al. Overall Survival with Ribociclib plus Endocrine Therapy in Breast Cancer. N Engl J Med 2019; 381: 307-316
• 27 Prat A, Chaudhury A, Solovieff N. et al. Correlative biomarker analysis of intrinsic subtypes and efficacy across the MONALEESA Phase III studies. San Antonio Breast Cancer Symposium 2020; 2020: GS1-04 Accessed March 16 2021at: https://www.abstractsonline.com/pp8/%23!/9223/presentation/665
• 28 Modi S, Park H, Murthy RK. et al. Antitumor Activity and Safety of Trastuzumab Deruxtecan in Patients With HER2-Low-Expressing Advanced Breast Cancer: Results From a Phase Ib Study. J Clin Oncol 2020; 38: 1887-1896
• 29 Bardia A, Tolaney SM, Loirat D. et al. ASCENT: A randomized phase III study of sacituzumab govitecan (SG) vs. treatment of physicianʼs choice (TPC) in patients (pts) with previously treated metastatic triple-negative breast cancer (mTNBC). Ann Oncol 2020; 31 (Suppl. 04) S1142-S1215 doi:10.1016/annonc/annonc325
• 30 Bardia A, Mayer IA, Vahdat LT. et al. Sacituzumab Govitecan-hziy in Refractory Metastatic Triple-Negative Breast Cancer. N Engl J Med 2019; 380: 741-751
• 31 Hurvitz SA, Tolaney SM, Punie K. et al. Biomarker evaluation in the phase 3 ASCENT study of sacituzumab govitecan versus chemotherapy in patients with metastatic triple-negative breast cancer. San Antonio Breast Cancer Symposium 2020; 2020: GS3-06 Accessed March 16 2021 at: https://www.abstractsonline.com/pp8/%23!/9223/presentation/674
• 32 Harbeck N, Johnston S, Fasching P. et al. High Ki-67 as a biomarker for identifying patients with high risk early breast cancer treated in monarchE. San Antonio Breast Cancer Symposium 2020; 2020: PD2-01 Accessed March 16 2021 at: https://www.abstractsonline.com/pp8/%23!/9223/presentation/781
• 33 Braun S, Marth C. Circulating tumor cells in metastatic breast cancer – toward individualized treatment?. N Engl J Med 2004; 351: 824-826
• 34 Cristofanilli M, Budd GT, Ellis MJ. et al. Circulating tumor cells, disease progression, and survival in metastatic breast cancer. N Engl J Med 2004; 351: 781-791
• 35 Janni WJ, Yab TC, Hayes DF. et al. Clinical utility of repeated circulating tumor cell (CTC) enumeration as early treatment monitoring tool in metastatic breast cancer (MBC) – a global pooled analysis with individual patient data. San Antonio Breast Cancer Symposium 2020; 2020: GS4-08 Accessed March 16 2021 at: https://www.abstractsonline.com/pp8/%23!/9223/presentation/685
• 36 Gray RG, Rea D, Handley K. et al. aTTom: Long-term effects of continuing adjuvant tamoxifen to 10 years versus stopping at 5 years in 6,953 women with early breast cancer. J Clin Oncol 2013; 31 (18 Suppl.): 5
• 37 Ma XJ, Salunga R, Dahiya S. et al. A five-gene molecular grade index and HOXB13:IL17BR are complementary prognostic factors in early stage breast cancer. Clin Cancer Res 2008; 14: 2601-2608
• 38 Bartlett J, Sgroi D, Treuner K. et al. Trans-aTTom: Breast Cancer Index for prediction of endocrine benefit and late distant recurrence (DR) in patients with HR+ breast cancer treated in the adjuvant tamoxifen – To offer more? (aTTom) trial. J Clin Oncol 2019; 37 (15 Suppl.): 505
• 39 Murthy RK, Loi S, Okines A. et al. Tucatinib, Trastuzumab, and Capecitabine for HER2-Positive Metastatic Breast Cancer. N Engl J Med 2020; 382: 597-609
• 40 Blondeaux E, Perachino M, Bruzzone M. et al. Chances of pregnancy after breast cancer, reproductive and disease outcomes: a systematic review and meta-analysis San Antonio Breast Cancer Symposium 2020; 2020: GS3-09 Accessed March 16 2021 at: https://www.abstractsonline.com/pp8/%23!/9223/presentation/677